Details for New Drug Application (NDA): 205412
✉ Email this page to a colleague
NDA 205412 describes ABACAVIR SULFATE AND LAMIVUDINE, which is a drug marketed by Pharmobedient, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Hetero Labs Ltd V, Laurus, Macleods Pharms Ltd, Teva Pharms Usa, and Zydus Pharms, and is included in ten NDAs. It is available from five suppliers. Additional details are available on the ABACAVIR SULFATE AND LAMIVUDINE profile page.
The generic ingredient in ABACAVIR SULFATE AND LAMIVUDINE is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
The generic ingredient in ABACAVIR SULFATE AND LAMIVUDINE is abacavir sulfate; lamivudine. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine profile page.
Summary for 205412
| Tradename: | ABACAVIR SULFATE AND LAMIVUDINE |
| Applicant: | Hetero Labs Ltd V |
| Ingredient: | abacavir sulfate; lamivudine |
| Patents: | 0 |
Pharmacology for NDA: 205412
| Mechanism of Action | Cytochrome P450 1A1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 205412
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ABACAVIR SULFATE AND LAMIVUDINE | abacavir sulfate; lamivudine | TABLET;ORAL | 205412 | ANDA | Camber Pharmaceuticals, Inc. | 31722-838 | 31722-838-30 | 1 BOTTLE in 1 CARTON (31722-838-30) / 30 TABLET, FILM COATED in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 600MG BASE;300MG | ||||
| Approval Date: | Apr 16, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
